Events

Date: Thursday, March 20th, 2025 Time: 2:00pm - 3:00pm ET       TITLE: Takeda FVIII Portfolio OBJECTIVE: Please join Takeda leadership to review Takeda FVIII Products & Resources Available. INTENDED AUDIENCE: All HTC staff SPEAKER: Anthea Cherednichenko, VP US Hematology Franchise Head Anthea leads the sales and marketing teams for Takeda’s Hematology portfolio. Anthea Read the full article...

Date: Thursday, April 3rd, 2025 Time: 2:00pm - 3:00pm ET         WEBINAR TOPIC: Alhemo (concizumab-mtci): A new option for patients living with hemophilia A or B with inhibitors OBJECTIVE: To provide a prescribing information overview of the recently FDA approved medication, Alhemo (concizumab-mtci), for patients living with hemophilia A or B with Read the full article...

Date: Tuesday, May 6th, 2025 Time: 2:00pm - 3:00pm ET         WEBINAR TOPIC: Complications and challenges associated with hemophilia and a rebalancing approach with HYMPAVZI™ (marstacimab-hncq) OBJECTIVES: Educate attendees on complications and challenges associated with hemophilia, the novel mechanism of action of HYMPAVZI, the BASIS Ph3 clinical trial results and dosage and Read the full article...

Date: Wednesday, May 7th, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TOPIC: Exploring data and expert perspectives on Qfitlia™ (fitusiran) OBJECTIVE: During this program, we will explore data and expert perspectives on Qfitlia™ (fitusiran), a newly approved prophylactic treatment for patients with hemophilia A and B, with or without inhibitors. SPEAKER: Vanessa Read the full article...

Date: Tuesday, May 13th, 2025 Time: 1:00pm - 2:00pm ET       WEBINAR TOPIC: A Collaborative Journey - ROCTAVIAN Patient & Provider Perspectives OBJECTIVE: Join us for an insightful webinar exploring the real-world experiences of patients and providers with ROCTAVIAN. Hear firsthand accounts of the treatment journey, from initial consultations and administration to outcomes Read the full article...